DS
CLDX icon

David Shaw’s Celldex Therapeutics CLDX Stock Holding History

David Shaw’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,380
Closed -$366K – 4225
2014
Q1 		$366K Sell
1,380
-167
-11% -$63.9K ﹤0.01% 3812
2013
Q4 		$562K Hold
1,547
– – ﹤0.01% 3646
2013
Q3 		$822K Buy
+1,547
New +$530K ﹤0.01% 3215

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's CLDX Position: Q2 2026 in Review

David Shaw reduced its Celldex Therapeutics (CLDX) stake by 66% in Q2 2026, selling an estimated $1.13M and leaving 17,826 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

David Shaw first reported a position in CLDX in Q2 2013 and has held it in 45 quarters since. The position peaked at $31.3M in Q2 2024. 252 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • David Shaw held 17,826 shares of Celldex Therapeutics worth $663K as of Q2 2026.
  • David Shaw sold 35,034 Celldex Therapeutics shares in Q2 2026, an estimated $1.13M.
  • Celldex Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4028 holding.
  • David Shaw first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 45 quarters since.
  • David Shaw's Celldex Therapeutics position peaked at $31.3M in Q2 2024.
  • 252 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.